CCIA
ALDX icon

Campbell & Co Investment Adviser’s Aldeyra Therapeutics ALDX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,569
Closed -$70.6K – 1076
2023
Q3 		$70.6K Sell
10,569
-718
-6% -$5.33K 0.01% 902
2023
Q2 		$94.7K Sell
11,287
-80,821
-88% -$796K 0.02% 842
2023
Q1 		$915K Buy
+92,108
New +$651K 0.17% 188

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Campbell & Co Investment Adviser's ALDX Position: Q4 2023 in Review

Campbell & Co Investment Adviser sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 10,569 shares — an estimated $70.6K sold.

Campbell & Co Investment Adviser first reported a position in ALDX in Q1 2023 and held it in 3 quarters. The position peaked at $915K in Q1 2023. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

  • Campbell & Co Investment Adviser reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 10,569 Aldeyra Therapeutics shares in Q4 2023, an estimated $70.6K.
  • Campbell & Co Investment Adviser first reported a position in Aldeyra Therapeutics in Q1 2023 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Aldeyra Therapeutics position peaked at $915K in Q1 2023.
  • 105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2023, filed 13 Feb 2024.